NCT Number: NCT06250465
For until very recently CLL has been considered an uncurable disease, with the only few exceptions of a part of patients capable of undergoing and successfully standing allogeneic stem cell transplant. However, the introduction of chemoimmunotherapy in particular the FCR (fludarabine, cyclophosphamide, rituximab) regimen has established a relevant population of IgVH mutated patients, who remain relapse-free for up to 10 years with a clear plateau at this level. However, for the largest proportion of all CLL patients the disease is still associated with a reduction in life expectancy as compared to a matched population.
The field has made further substantial progress by the introduction of BTK inhibitors and Bcl2 inhibitors, novel antibodies as well as by the understanding of the role of minimal residual disease (MRD), mutations and their clonal evolution over time as risk factors and factors governing the kind and duration of therapy.
Due to the limited follow up of frontline therapy trials using novel drugs, it is not yet clear, what the long-term results with many of the new drugs will be. Particularly, long-term PFS, the potential for cure and the long-term safety issues remain relevant parameters requiring examination, as are infections, interactions with other drugs or quality of life issues.
CLL has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of this disease.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Landeskrankenhaus Feldkirch, Innere Med. II, Interne E, Feldkirch, Austria
This registry is designed as multicenter observational cohort of patients with CLL. Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up.
For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic Case Report Forms. To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry.
A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 7 years
To describe general characteristics of CLL patients
Time frame: 7 years
To describe genetic risk profiles
Time frame: 7 years
To describe the proportion of CLL patients in Austria that require treatment
Time frame: 7 years
To describe concomitant diseases at diagnosis of CLL
Time frame: 7 years
To describe type and duration of treatment of CLL. Number of patients per treatment, number of treatments per patient.
Time frame: 7 years
To describe patient outcome (complete response, partial response...) in relation to the type of treatment administered.
Time frame: 7 years
To describe toxicity with a focus on infections, cardiotoxicity, nephrotoxicity, bleeding, etc.
Contact information is provided by the study sponsor or research team.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06967610
Chronic Disease, Chronic Lymphocytic Leukemia
Houston, Texas, United States
View Trial DetailsNCT04269902
Chronic Disease, Chronic Lymphocytic Leukemia
Birmingham, Alabama, United States
View Trial DetailsNCT07020533
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Duarte, California, United States
View Trial DetailsNCT06973187
Chronic Disease, Chronic Lymphocytic Leukemia
Birmingham, Alabama, United States
View Trial Details